This commentary came by way of ltr a reader at Angry Bear. A pretty solid review of how drug prices and the resulting costs after insurance are still impossible to pay. That is, if the insurance, Medicare, Medicaid even pay for them in entirety or a portion. If the former is not the case, a […]
What I like about this Issue-Brief is the use of terminology we see, not knowing what it means, and seeing a description or definition. I have added links so as to do a deeper dive into the terminology. Carefully read, a person can garner an understanding of initial drug costs, intermediate costs, discounts, and what […]
Commenter Arne asked how we would transition from today’s healthcare system to a Single Payer format. I do not have the answer immediately at hand. I have to look for it. I do want to review what we have learned to date and stated on Angry Bear already. I do have a number of posts […]
Medicare is almost $200 billion in gross drug spend: Who gets the blame? — 46brooklyn Research This is a complex issue as there are many moving parts to drug pricing and their costs. Perplexing in describing the drug spend issues would seem appropriate. I am not even sure if this long post will adequately define […]
“What the Inflation Reduction Act means for PBMs” Times of News This is a strange little article trying to fill a gap in knowledge. The italicized sentences are mine. It does make some sound points on PBMs so I kept it. If you can get into Seeking Alpha or Modern Healthcare, you may find a […]
Inflation Reduction Act The Inflation Reduction Act drug price negotiation is small in returns, low in the number of drugs initially impacted, and slow to start. Ten drugs will be selected and the impact of the act begins in 2026. It rises to 20 drugs to be negotiated in 2029. The new act ignores European […]
“The Justice Department moved on Thursday to block a bankruptcy plan that grants broad legal immunity to the pharmaceutical company Purdue Pharma, whose drug OxyContin has been at the heart of the nation’s opioid epidemic. William K. Harrington, the U.S. trustee for the Justice Department, filed a motion in federal court to halt confirmation of […]
Guest Author at Angry Bear is Professor Joel Eissenberg. Dr. Joel Eissenberg is a professor of Biochemistry and Molecular Biology and is probably a good source to ask questions concerning pandemics and bringing new vaccines to market. Ask questions . . . I am sure he will answer the same as he has commented in […]
How Pharma Influences Legislation They Do Not Like From 2006 to 2015, pharmaceutical companies spent $880 million in lobbying state and federal legislatures and contributing to campaigns to prevent laws restricting Opioid prescriptions. Their lobbying expenditures has outstripped those advocating for greater controls on prescriptions by 200 times giving them greater influence at the state […]